-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11

Benzinga·09/10/2026 14:37:36
語音播報
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.